Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OZINE-PR
- Development stage
- Unknown
- Lead developer
- Opdenas Lifesciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
OZINE-PR is a combination oral pharmaceutical product marketed by Opdenas Lifesciences for the prophylaxis of migraine. It consists of flunarizine (10 mg), a calcium channel blocker that targets voltage-gated calcium channels to reduce neuronal excitability, and propranolol hydrochloride (40 mg) in a sustained-release formulation, which acts as a non-selective beta-adrenergic receptor antagonist to decrease sympathetic activity. This dual-action mechanism stabilizes reactive nerve cells and increases the threshold for migraine activation, thereby reducing the frequency, severity, and duration of migraine attacks. The sustained-release formulation of propranolol ensures long-lasting protection for patients suffering from chronic migraines.
- Brand names
- OZINE-PROZINE PR TAB
- Other names
- Flunarizine + Propranolol SR
02
Targets
ADRB1 (β1)ADRB2 (β2)CaV (Voltage-gated calcium channel protein complex)
Beyond the preview
Go deeper on OZINE-PR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OZINE-PR.